Skip to main content
. 2009 Jan;20(1):68–77. doi: 10.1681/ASN.2008010036

Figure 2.

Figure 2.

Imatinib attenuates glomerulonephritis in TSLP-Tg mice. (A) TSLP-Tg mice treated with vehicle (middle) develop progressive accumulation of matrix and deposits of IC compared with WT mice (top). Treatment with imatinib dramatically reduces extracellular matrix expansion and IC deposits in TSLP-Tg mice at each time point (bottom), and depicted graphically in Supplemental Figure 7. (B) Treatment with imatinib attenuates renal injury in TSLP-Tg mice with decreased glomerular matrix deposition (collagen type IV expression) and mesangial cell activation (α-SMA expression), despite increased glomerular macrophage influx (Mac-2 expression), shown graphically in Supplemental Figure 7. Glomerular cellularity is not statistically affected by imatinib treatment (hematoxylin and eosin [H & E] stain), shown graphically in Supplemental Figure 7. Magnification, ×400.